Advertisement

Journal of Neuro-Oncology

, Volume 145, Issue 2, pp 357–364 | Cite as

Treatment strategies for glioblastoma in older patients: age is just a number

  • Michael Youssef
  • Ethan B. Ludmir
  • Jacob J. Mandel
  • Akash J. Patel
  • Ali Jalali
  • Jeffrey Treiber
  • Jimin Wu
  • Mary Frances McAleer
  • John F. de GrootEmail author
Clinical Study

Abstract

Background/purpose

Optimal care for elderly patients with glioblastoma (GBM) remains in question due to their exclusion from and underrepresentation in many clinical trials (including EORTC 22,981) as well as their historically poor overall survival.

Methods

A retrospective chart review was conducted at a single high-volume cancer center for newly diagnosed elderly (65 years old or older) GBM patients diagnosed from 2011 through 2017.

Results

A total of 158 newly diagnosed GBM patients aged 65 years and older were identified. One hundred forty-four patients (91.1%) received radiotherapy (RT) and 130 patients (90.3%) received concurrent temozolomide with RT. Sixty-one patients (38.6%) completed concurrent chemoradiation and 6 cycles of adjuvant temozolomide. 23% of patients discontinued temozolomide during concurrent or adjuvant treatment due to side effects or complications of chemotherapy.

With a median follow-up time of 35.0 months, median overall survival (OS) time for the full cohort was 18.6 months, with estimated OS rates of 74.8%, 35.9%, and 9.5% at 1, 2, and 5 years, respectively. On multivariable analysis, higher KPS (p = 0.002, HR 0.46; 95% CI 0.63–0.82), completing planned RT course (p = 0.01, HR 0.29; 95% CI 0.11–0.75), and completing 6 cycles of adjuvant temozolomide (p = 0.01, HR 2.62; 95% CI 1.67–4.12) were independently associated with improved OS.

Conclusions

Our cohort of elderly GBM patients was predominantly treated with standard of care therapy based on EORTC 22,981. Despite their age, these patients generally tolerated treatment well and had favorable outcomes compared to those reported for patients treated on EORTC 22,981. Based on these findings, using advanced age as the basis for treatment de-escalation or as an exclusionary criterion in clinical trials should be discouraged.

Keywords

Elderly Glioblastoma Hypofractionated MGMT Overall survival Radiotherapy Temozolomide Adjuvant Concurrent 

Notes

Author contributions

MY (data curation, formal analysis, writing—original draft, writing—review and editing), EBL (data curation, formal analysis, writing - original draft,writing—review and editing), JJM (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing), JT (data curation, writing—review and editing, AJP (data curation, writing—review and editing), AJ (data curation, writing—review and editing), MFM (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing), JFG (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing).

Funding

No funding was obtained for this project.

Compliance with ethical standards

Conflict of interest

Dr. John de Groot—Grant or Research Support: Sanofi-Aventis, Astrazeneca, EMD-Serono; Eli Lilly, Novartis, Deciphera Pharmaceuticals, Mundipharma; Paid Consultant: Celldex; Deciphera Pharmaceuticals, AbbVie, FivePrime Therapeutics, Inc., GW Pharma, Carthera, Eli Lilly, Boston Biomedical Inc.,Taiho Pharmaceuticals, Kairos Venture Investments, Syneos Health, Monteris, Agios, Mundipharma, Blue Earth Diagnostics; Advisory Boards: Genentech, Celldex, Foundation Medicine, Inc., Novogen, Deciphera, Astrazeneca, Insys Therapeutics, Kadmon, Merck, Eli Lilly, Novella Clinical, Blue Earth Diagnostics; Other Relevant Financial or Material Interests: DSMB: VBL Therapeutics; DSMB: Novella; VBI Vaccines, Inc.; Stock Ownership: Ziopharm Oncology, Gilead; Company Employment (Spouse): Ziopharm Oncology. None of the other authors have any conflict of interests to report.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors and was a retrospective study performed with approval of the IRB of the respective institutions.

Supplementary material

11060_2019_3304_MOESM1_ESM.docx (33 kb)
Supplementary file1 (DOCX 32 kb)

References

  1. 1.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.  https://doi.org/10.1056/NEJMoa043330 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ (2013) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39:350–357.  https://doi.org/10.1016/j.ctrv.2012.05.008 CrossRefPubMedGoogle Scholar
  3. 3.
    Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E (2001) A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:100–107CrossRefGoogle Scholar
  4. 4.
    Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial I (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037.  https://doi.org/10.1056/NEJMoa1611977 CrossRefPubMedGoogle Scholar
  5. 5.
    Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncology 20:iv1–iv86.  https://doi.org/10.1093/neuonc/noy131 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588.  https://doi.org/10.1200/JCO.2004.06.082 CrossRefPubMedGoogle Scholar
  7. 7.
    Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, Nordic Clinical Brain Tumour Study G (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926.  https://doi.org/10.1016/S1470-2045(12)70265-6 CrossRefGoogle Scholar
  8. 8.
    Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, Society NOASGoN-oWGoGC (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715.  https://doi.org/10.1016/S1470-2045(12)70164-X CrossRefGoogle Scholar
  9. 9.
    Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W (2018) Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. J Neurooncol 140:421–426.  https://doi.org/10.1007/s11060-018-2969-3 CrossRefPubMedGoogle Scholar
  10. 10.
    Seppälä M, Raj R, Korja M, Pitkäniemi J, Seppä K, Malila N, Luostarinen T, Mäenpää H (2018) Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro-oncology 21:370–379.  https://doi.org/10.1093/neuonc/noy164 CrossRefGoogle Scholar
  11. 11.
    Huang B, Liu M, Villano JL, Pittman T, Garcia CR, Dolecek TA, Dressler EV (2018) Patterns and disparities of care in glioblastoma. Neuro-oncol Pract 6:37–46.  https://doi.org/10.1093/nop/npy014 CrossRefGoogle Scholar
  12. 12.
    Wick A, Kessler T, Elia AEH, Winkler F, Batchelor TT, Platten M, Wick W (2018) Glioblastoma in elderly patients: solid conclusions built on shifting sand? Neuro-oncology 20:174–183.  https://doi.org/10.1093/neuonc/nox133 CrossRefPubMedGoogle Scholar
  13. 13.
    Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535.  https://doi.org/10.1056/NEJMoa065901 CrossRefPubMedGoogle Scholar
  14. 14.
    Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O (2018) One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neurooncol 140:385–391.  https://doi.org/10.1007/s11060-018-2964-8 CrossRefPubMedGoogle Scholar
  15. 15.
    Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM (2018) Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. J Neurooncol 138:155–162.  https://doi.org/10.1007/s11060-018-2782-z CrossRefPubMedGoogle Scholar
  16. 16.
    Bingham B, Patel CG, Shinohara ET, Attia A (2018) Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: a National Cancer Database Analysis. J Neurooncol 136:385–394.  https://doi.org/10.1007/s11060-017-2665-8 CrossRefPubMedGoogle Scholar
  17. 17.
    Lu VM, Kerezoudis P, Brown DA, Burns TC, Quinones-Hinojosa A, Chaichana KL (2019) Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. J Neurooncol.  https://doi.org/10.1007/s11060-019-03155-6 CrossRefPubMedGoogle Scholar
  18. 18.
    Mak KS, Agarwal A, Qureshi MM, Truong MT (2017) Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med 6:1192–1200.  https://doi.org/10.1002/cam4.1070 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874CrossRefGoogle Scholar
  20. 20.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003.  https://doi.org/10.1056/NEJMoa043331 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G (2018) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-oncology 21:167–178.  https://doi.org/10.1093/neuonc/noy132 CrossRefGoogle Scholar
  22. 22.
    Lassman A, Dimino C, Mansukhani M, Murty V, Ansell PJ, Bain E, Holen KD, Roberts-Rapp LA, Lee J, Curran W, Mehta MP, Canoll P (2017) ACTR-68. Concordance of EGFR and MGMT analyses between local and central laboratories: implications for clinical trial design and precision medicine for depatuxizumab-mafodotin (ABT-414) in glioblastoma (GBM). Neuro-oncology 19:vi15.  https://doi.org/10.1093/neuonc/nox168.055 CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu A-L, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W (2018) Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-oncology 20:367–379.  https://doi.org/10.1093/neuonc/nox160 CrossRefGoogle Scholar
  24. 24.
    Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A (2017) Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-oncology 19:394–404.  https://doi.org/10.1093/neuonc/now189 CrossRefGoogle Scholar
  25. 25.
    Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Muller W, Plass C, Weller M, Wick W, Neuro-oncology Working Group of the German Cancer S (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology 15:1017–1026.  https://doi.org/10.1093/neuonc/not043 CrossRefGoogle Scholar
  26. 26.
    DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, Lennerz JK (2017) Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-oncology 19:1640–1650.  https://doi.org/10.1093/neuonc/nox120 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ludmir EB, Mandel JJ, McAleer MF, de Groot JF (2019) Disparities along the glioblastoma clinical trials landscape. Neuro-oncology 21:285–286.  https://doi.org/10.1093/neuonc/noy176 CrossRefPubMedGoogle Scholar
  28. 28.
    Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM (2018) The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-oncology 20:1034–1043.  https://doi.org/10.1093/neuonc/noy027 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466.  https://doi.org/10.1016/s1470-2045(09)70025-7 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neuro-OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Neurology and NeurosurgeryBaylor College of MedicineHoustonUSA
  3. 3.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Division of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations